respiratory syncytial virus rsv through mrna technology clinical trial intelligence

A Phase 1, First-Time-in-Human (FTiH), Observer-blind, Randomized, Controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of Various Doses of an mRNA-based Respiratory Syncytial Virus (RSV) Investigational Vaccine in Healthy Participants 18-45 Years of Age

GlaxoSmithKline (GSK) is advancing an mRNA-based vaccine targeting Respiratory Syncytial Virus (RSV) in a Phase 1 clinical trial. The trial aims to evaluate the safety, reactogenicity, and immune response of various vaccine formulations in healthy adults aged 18-45. Given the significant unmet medical need for effective RSV vaccines, particularly in vulnerable populations such as infants and the elderly, successful outcomes could position GSK favorably in a competitive landscape that includes other mRNA vaccine developers. The trial's active status, despite not currently recruiting, indicates ongoing commitment to this asset, with potential implications for future partnerships or licensing opportunities. The market for RSV vaccines is expected to grow, driven by increasing awareness and demand for preventive measures against respiratory infections.

Matched by target_normalized: Respiratory Syncytial Virus (RSV) through mRNA technology